|[May 19, 2014]
Pulmonx Announces First Comprehensive Report of Collateral Ventilation Assessed by the Chartis Endobronchial Catheter in Late Stage Emphysema
REDWOOD CITY, Calif. --(Business Wire)--
an emerging leader in interventional pulmonology, announced today that
multiple clinical abstracts examining the diagnostic and therapeutic
utility of its Chartis Pulmonary Assessment System and Zephyr®
Endobronchial Valve (EBV) are being presented at the American Thoracic
Society International Conference in San Diego. The Zephyr® EBV is
commercially available in Europe as well as other international markets
and is an investigational device in the United States.
Of particular interest, the Chartis Pulmonary Assessment System was
featured during a symposium in the presentation titled "New COPD
subgroups according to prevalence and distribution of interlobar
collateral ventilation assessed by an endobronchial catheter system."
Historically, prevalence and distribution of Collateral Ventilation (CV)
in emphysematous lungs are not well described and studied
endobronchially under physiological conditions. This study marks the
first comprehensive investigation of the presence of Collateral
Ventilation by lobe in a large patient population. The retrospective
study included the analysis of 325 Chartis assessments conducted in 125
COPD patients with severe emphysema.
The results of this study indicate that approximately 70% of upper lobe
predominant disease patients should have a CV- (absence of Cllateral
Ventilation) target for valve therapy and approximately 45% of lower
lobe predominant disease patients should have a CV- target.
"It appears that many late stage emphysema patients may be candidates
for EBV therapy based on this extensive data set", said Ralf H. Hübner,
M.D., Charité University, Department of Internal Medicine, Division of
Infectious Diseases and Pulmonary Medicine. "These study results
reinforce what I have generally experienced in my own practice."
This dataset represents the largest retrospective analysis to-date using
the Chartis Pulmonary Assessment System. The authors concluded that more
than two-thirds of all patients had at least one CV- lung lobe and were
potentially good candidates for the Zephyr EBV therapy.
Further information on this study and the other abstracts may be found
The Zephyr® Endobronchial Valve is a minimally invasive device intended
to treat patients with emphysema. Emphysema patients suffer from
hyperinflation, an increase in volume of the diseased portions of their
lungs, which then compresses the healthier areas. The Zephyr® EBV
therapy involves bronchoscopic placement of one-way valves designed to
reduce the hyperinflation in the diseased portion of the lungs, thereby
improving the ability of the healthier portions of the lungs to
function. The Zephyr® EBV received the CE Mark in 2003. Since becoming
commercially available in Europe and select countries worldwide, the
company estimates that it has been used to treat over 7,500 patients.
The Pulmonx Chartis Pulmonary Assessment System provides pulmonologists
with lobe-specific information about a patient's lung, enabling
physicians to plan valve treatments to account for anatomical variations
in the lungs of individual patients which impact the effectiveness of
the valves. The addition of the Pulmonx Chartis assessment now ensures
that a very high percent of treated patients will experience benefit
from EBV treatment. The Chartis Pulmonary Assessment System and
accessories are FDA 510(K) cleared devices.
Pulmonx, based in Redwood City, California, and Neuchâtel, Switzerland,
is focused on developing and marketing minimally invasive medical
devices and technologies for the diagnosis and treatment of pulmonary
The Zephyr® EBV is an investigational device in the United States.
Limited by U.S. law to investigational use.
[ Back To Technology News's Homepage ]